Trial Profile

An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Feb 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivoceranib (Primary)
Indications Adenocarcinoma; Gastric cancer
Focus Adverse reactions
Acronyms AHEAD-G202

Most Recent Events

05 Jun 2018 According to results presented at 54th Annual Meeting of the American Society of Clinical Oncology, 391 patients were enrolled between Mar 2015 and Dec 2017.
05 Jun 2018 Results (n=391) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
20 Jan 2018 Results (n=326) assessing the safety and efficacy of apatinib in the real world with wider inclusion criteria, presented at the 2018 Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com